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ABSTRACT
Background and Objectives: Associations have been reported between the serum uric acid (SUA) level, metabolic syndrome 
(MS), and atherosclerosis. We have determined the relationship between the SUA level, MS, and arterial stiffness in Korean. 
Subjects and Methods: Cross-sectional data from 1,276 adults who underwent routine laboratory tests and pulse wave ve-
locity (PWV) measurements during a health check-up were analyzed in a gender-specific manner. None of the participants 
had atherosclerotic cardiovascular disease, diabetes, renal disease, or systemic disease, or were under treatment which would 
affect SUA levels, or taking medications for hypertension or dyslipidemia. Results: After adjustment for age, smoking sta-
tus, total cholesterol (TC), and creatinine, the odds ratios (ORs, 95% confidence interval) of gender-specific quartiles of SUA 
for MS were 1.0, 1.28 (0.66-2.47), 1.46 (0.76-2.82), and 2.21 (1.15-4.26) in females, and 1.0, 1.33 (0.82-2.17), 1.60 (0.96-2.66), 
and 2.03 (1.21-3.40) in males. However, after adjustment for waist circumference, there were no significant differences in 
the ORs among the SUA quartile groups in females and males (both, p=NS). The Pearson’s correlation coefficients for the re-
lationship between SUA levels and heart-femoral (hf) PWVs or brachial-ankle (ba) PWVs were not significant in females and 
males (r=0.054 and r=0.015, respectively, in females; r=-0.036 and r=-0.015, respectively, in males; all, p=NS). Conclusion: An 
elevated SUA level is associated with abdominal obesity among the MS components, but the SUA level is not associated with 
PWV in females or males. (Korean Circ J 2010;40:314-320)
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Introduction
Elevated serum uric acid (SUA) levels often exist in patients 
with metabolic syndrome (MS), and cross-sectional studies 
among various ethnic groups have shown that the prevalence 
of MS increases with increasing SUA levels.
1-4) Epidemiologic 
studies have also shown associations between SUA levels and 
the components of MS,
5-7) suggesting that hyperuricemia 
could be an additional component of MS. Moreover, the SUA 
level is increasingly elevated as the number of components of 
MS increases.
1)6) However, strong intercorrelations among 
SUA levels and the variables of MS included in the diagnos-
tic criteria
8) make it difficult to determine whether or not an 
elevated SUA level is an additional active component of MS 
or just an associative link to MS or its components. Further-
more, the relationship between SUA levels, MS, and its vari-
ables still needs to be delineated in Korean subjects because 
clustering of risk factors is not the same among different eth-
nic groups.
9)
Large epidemiologic studies have suggested that hyperuri-
cemia may be a risk factor for cardiovascular disease.
10)11) The 
association between SUA levels and cardiovascular disease 
may in part be attributable to cardiovascular risk factors clus-
tering in subjects with MS. Moreover, a few studies have shown 
that the SUA level is independently associated with cardio-Ji Hyon Lim, et al.   315
vascular mortality,
12) and atherosclerosis, including coronary 
artery calcifications
13) and carotid atherosclerosis.
3)14) Regard-
less of the role of the SUA level as an independent risk factor 
or marker for atherosclerosis, few studies have examined the 
relationship between SUA levels and arterial stiffness, which 
is also a surrogate marker of atherosclerosis.
15)16) In particular, 
the available data are very limited on the relationship between 
SUA levels and pulse wave velocity (PWV), an index of arte-
rial stiffness, even in Japanese individuals, despite the wide use 
of the automated measure of PWV in Japan.
17) Moreover, it 
is unknown whether or not the SUA level is associated with 
PWV in Korean. 
Therefore, in the present study we first determined the re-
lationship between SUA levels, MS, and its variables. Then, we 
determined whether or not the SUA level is associated with 
PWV in Korean adults.
Subjects and Methods
Subjects
The present study included 1,276 adults, 20-80 years of age, 
who attended the Health Promotion Center and Outpatient 
Clinic of the Cardiovascular Center of Dongguk University 
Ilsan Hospital in Goyang, Korea between July 2005 and Au-
gust 2007. The medical history, symptoms,  and cigarette sm-
oking were confirmed by the consulting physicians. All of 
the participants underwent the following laboratory tests as 
part of their health check-ups: routine blood tests, urinalysis, 
electrocardiography (ECG), chest radiography, and PWV 
measurement. 
Subjects with atherosclerotic cardiovascular disease, dia-
betes, established renal disease (serum creatinine >1.4 mg/dL 
in females and >1.5 mg/dL in males), and systemic diseases, 
such as hyper- or hypo-thyroidism and gout, were excluded. 
Participants currently taking antihypertensives, lipid-lower-
ing drugs, uricosuric agents, and hormone replacement for 
menopause were also excluded.
Blood chemistry 
Blood samples were obtained after the participants had fast-
ed overnight. Serum levels of total cholesterol (TC), triglyc-
erides, high density lipoprotein-cholesterol (HDL-C), fasting 
plasma glucose, creatinine, and uric acid were determined by 
standard automated bioassays (Modular DPE; Roche Diag-
nostics, Mannheim, Germany). 
The SUA level was measured by the uricase-peroxidase me-
thod. The mean SUA level was significantly lower in females 
(4.3±0.9 mg/dL) than males (6.0 ±1.3 mg/dL, p<0.001). Th-
erefore, gender-specific quartiles of the SUA levels were used. 
Gender-specific SUA quartiles were as follows: 1.9-3.6, 3.7-
4.2, 4.3-4.9, and 5.0-8.6 mg/dL in females; and 1.9-5.1, 5.2-6.0, 
6.1-6.8, and 6.9-10.1 mg/dL in males.
Measurement of pulse wave velocity
Arterial stiffness was assessed by measuring the heart-fem-
oral (hf) and brachial-ankle (ba) PWVs using an automatic 
waveform analyzer (VP-2000; Colin Co., Komaki, Japan).
15)16)18) 
The VP-2000 simultaneously records pulse waves, blood pres-
sure (BP; both arms and ankles), ankle-brachial pressure index 
(ABI), ECG, and heart sounds, as described elsewhere.
15)16) 
Pearson’s correlation coefficients of intra- and inter-observer re-
producibility of hfPWV and baPWV were as follows, as desc-
ribed elsewhere:
15) hfPWV (r=0.912 and r=0.802, respective-
ly); and baPWV (r=0.976 and 0.972, respectively). All partici-
pants included in the present study had a normal ABI (>0.9). 
A high hfPWV or baPWV was defined as the gender-specific 
highest quartile of the values among the study subjects {hfP-
WV ≥900 cm/s in females and ≥968 cm/s in males; baPWV 
(the mean of the right and left values) ≥1,490 cm/s in females 
and ≥1,509 cm/s in males}.
Definition of metabolic syndrome 
Using the modified National Cholesterol Education Pro-
gram Adult Treatment Panel Guideline III
8) and central obe-
sity criteria for Korean,
19) participants with ≥3 of the follow-
ing criteria were diagnosed with MS: 1) central obesity (waist 
circumference ≥85 cm in females; and ≥90 cm in males); 2) 
elevated fasting plasma glucose (≥100 mg/dL); 3) elevated 
triglycerides (≥150 mg/dL); 4) low HDL-C (<50 mg/dL in 
females; and <40 mg/dL in males); and 5) elevated BP (≥130/ 
85 mmHg). The BP recorded was the higher BP measured in 
both arms by oscillomety in a supine position during PWV 
measurement. Smoking was defined as any cigarette use in the 
past month.
Statistical analysis 
The data are expressed as the mean±SD, percentage, and 
the mean with 95% confidence interval. Before statistical an-
alysis, the levels of triglycerides and creatinine were log-trans-
formed because of the skewed distribution. Differences be-
tween groups were tested by Student’s t-test, χ2 test, one-way 
analysis of variance, and analysis of covariance, when appro-
priate. The relationships between SUA levels, the variables of 
MS, and the PWV values were assessed by Pearson’s correla-
tion coefficients. The relationship between the SUA quartiles 
and MS was evaluated by logistic regression analysis. We cal-
culated the unadjusted odds ratios (ORs) and multivariate 
ORs of gender-specific SUA quartiles for MS using the lowest 
quartile as a reference. 
In model 1, we adjusted for age, smoking, TC, and creati-
nine. In model 2, we added waist circumferences among the 
variables of MS. All statistical analyses were performed using 
Statistical Package for the Social Sciences (SPSS), version 11.5 
(SPSS, Chicago, IL, USA). A p<0.05 was considered statistical-
ly significant.316   Uric Acid, Metabolic Syndrome, and Arterial Stiffness
Results
Characteristics of the subjects
Among a total of 1,276 subjects, 583 were females and 693 
were males. The mean age was 48.3±10.1 years. The mean 
body mass index was 24.2±3.1 kg/m
2. The Framingham 10-
year coronary heart disease (CHD) risk was 4±5%. Among 
1,276 subjects, 30.1% had a systolic BP ≥140 mmHg or a dia-
stolic BP ≥90 mmHg, and 24.8% had MS. Current smokers 
comprised 24.6% of the participants. The SUA level and other 
variables significantly differed between females and males (Ta-
ble 1).
Relationship between serum uric acid levels and the 
variables of metabolic syndrome
In females and males, the SUA levels were significantly and 
positively correlated with waist circumference and log triglyc-
erides, but not with BP (systolic or diastolic) and fasting glu-
cose. SUA levels were significantly and negatively correlated 
with HDL-C in males, but not in females (Table 2). SUA levels 
increased significantly with an increasing number of MS com-
ponents (0, 1, 2, and ≥3) in females and males (both, p for lin-
ear trend <0.005) (Fig. 1). 
Relationship between serum uric acid levels and me-
tabolic syndrome status
Females with MS (n=120) had higher SUA levels than fe-
males without MS (n=463; 4.6±1.1 vs. 4.2±0.9 mg/dL, p< 
0.001). Males with MS (n=196) also had higher SUA levels 
than males without MS (n=497; 6.2±1.3 vs. 5.9±1.3 mg/dL, 
p=0.006). The differences retained significance after adjust-
ment for age, smoking, TC, and creatinine in females (p=0.014) 
and males (p=0.011).
The prevalence of MS according to the gender-specific SUA 
quartile is shown in Fig. 2. In females and males, the preva-
lence of MS increased gradually with increasing SUA quar-
tiles (both, p for linear trend <0.005). There were graded in-
creases in the unadjusted ORs for the association between 
increasing SUA levels and MS. Similarly, increasing trends 
of the multivariate ORs persisted in model 1. However, after 
additional adjustment for waist circumference (model 2), th-
ere were no significant differences in the multivariate ORs 
Table 1. Characteristics of the study participants according to gender
Variables Total (n=1,276) Females (n=583) Males (n=693) p
Age (years) 48.3±10.1 49.7±10.0 47.1±10.0 <0.001
BMI (kg/m
2)  24.2±3.1 23.6±3.3 24.7±2.8 <0.001
WC (cm) 83.8±9.2 79.6±9.0 87.3±7.7 <0.001
Systolic BP (mmHg) .129±20 .127±22 .131±18 0.001
Diastolic BP (mmHg) .080±13 .077±13 .083±12 <0.001
Fasting glucose (mg/dL) .093±10 .092±10 .094±10 0.002
Total cholesterol (mg/dL) .197±35 .194±35 .199±35 0.010
Triglycerides (mg/dL) .120±2 .102±2 .137±2 <0.001
HDL-C (mg/dL) .056±15 .060±16 .051±12 <0.001
Smoking (%) 24.6 6.4 40.1 <0.001
Creatinine (mg/dL) 0.9±1.3 0.7±1.2 1.0±1.2 <0.001
Uric acid (mg/dL) 5.2±1.4 4.3±0.9 6.0±1.3 <0.001
No. of MS components (n) 1.6±1.3 1.4±1.3 1.7±1.3 <0.001
MS (%) 24.8 20.6 28.3 0.002
BP ≥140/90 mmHg (%) 30.1 24.2 35.1 <0.001
Framingham 10-year risk (%) 4±5 2±2 7±5 <0.001
hfPWV (cm/s) 862±159 830±161 888±153 <0.001
baPWV (cm/s) 1379±2520 1354±2780 1400±2270 0.001
Values are the mean±SD or percentage. For levels of triglycerides and creatinine, the mean values are expressed as the geometric mean because 
of the skewed distribution. baPWV: brachial-ankle pulse wave velocity, BMI: body mass index, BP: blood pressure, HDL-C: high density li-
poprotein-cholesterol, hfPWV: heart-femoral pulse wave velocity, MS: metabolic syndrome, WC: waist circumference
Table 2. Pearson's correlation coefficients between serum uric 
acid level and metabolic syndrome variables
Female p Male p
WC (cm) 0.173 <0.001 0.212 <0.001
Systolic BP (mmHg) -0.029 0.492 0.035 0.356
Diastolic BP (mmHg) 0.034 0.418 0.038 0.316
Fasting glucose (mg/dL) 0.054 0.189 0.007 0.851
Log triglycerides (mg/dL) 0.163 <0.001 0.180 <0.001
HDL-C (mg/dL) -0.070 0.092 -0.138 <0.001
BP: blood pressure, HDL-C: high density lipoprotein-cholesterol, 
WC: waist circumference Ji Hyon Lim, et al.   317
among the SUA quartile groups in both genders (both, p= 
NS) (Table 3).
Relationship between serum uric acid levels and 
pulse wave velocity 
The prevalence of high hfPWV or high baPWV was neither 
different nor increasing among participants in the first, sec-
ond, third, or fourth SUA quartiles of both genders (Figs. 3 
and 4). Furthermore, Pearson’s correlation coefficients for 
the relationship between SUA levels and hfPWV or baPWV 
were not significant in both genders (r=0.054 and r=0.015, re-
spectively, in females; and r=-0.036 and r=-0.015, respective-
ly, in males; all, p=NS).
Discussion
In the present study, we showed that an elevated SUA level 
is associated with MS, but the association is dependent on 
waist circumference. Further, SUA is not associated with PWV 
in Korean adults.
In our study population, SUA levels were significantly and 
positively associated with waist circumference and triglycer-
ides in both genders, and significantly and negatively associ-
ated with HDL-C in males. These relationships are generally 
similar to those reported in previous cross-sectional stud-
ies.
1)3)4)6)7) The Pearson’s correlation coefficient between the 
SUA level and waist circumference was the highest value in 
females and males, which is compatible with the finding that 
Table 3. Prevalence of metabolic syndrome and odds ratio for metabolic syndrome according to the serum uric acid quartile
Q1 Q2 Q3 Q4
Whole
Subjects (n) 321 343 319 293
Prevalence 17.8 (13.6-22.0) 23.9 (19.4-28.4) 25.4 (20.6-30.2)* 32.8 (27.4-38.2)
Unadjusted 1 (reference) 1.46 (0.99-2.12) 1.58 (1.08-2.31)* 2.26 (1.55-3.29)†
Model 1 1 (reference) 1.37 (0.93-2.02) 1.60 (1.07-2.38)* 2.32 (1.55-3.45)†
Model 2 1 (reference) 1.00 (0.64-1.57) 1.00 (0.63-1.59)* 1.37 (0.86-2.17)
Females
Subjects (n) 148 148 152 135
Prevalence 13.5 (8.0-19.0)0 19.6 (13.2-26.0) 20.4 (14.0-26.8)* 29.6 (21.9-37.3)
Unadjusted 1 (reference) 1.56 (0.84-2.91) 1.64 (0.89-3.03)* 2.70 (1.48-4.90)‡
Model 1 1 (reference) 1.28 (0.66-2.47) 1.46 (0.76-2.82)* 2.21 (1.15-4.26)*
Model 2 1 (reference) 1.06 (0.50-2.26) 1.13 (0.54-2.38)* 1.62 (0.77-3.42)
Males
Subjects (n) 173 195 167 158
Prevalence 21.4 (15.3-27.5) 27.2 (21.0-33.4) 29.9 (23.0-36.8)* 35.4 (27.9-42.9)
Unadjusted 1 (reference) 1.37 (0.85-2.22) 1.57 (0.96-2.57)* 2.02 (1.24-3.29)‡
Model 1 1 (reference) 1.33 (0.82-2.17) 1.60 (0.96-2.66)* 2.03 (1.21-3.40)‡
Model 2 1 (reference) 0.92 (0.52-1.63) 0.95 (0.52-1.73)* 1.10 (0.60-2.01)
Values are the number of subjects, % of prevalence, and odds ratio (95% CI). Model 1:  adjusted for age, smoking, total cholesterol, creatinine 
(females or males), and gender (whole). Model 2: adjusted for age, smoking, total cholesterol, creatinine, waist circumference (females or 
males), and gender (whole). *p<0.05, †p<0.001, ‡p<0.01 vs. the lowest quartile (reference)
Fig. 2. Prevalence of metabolic syndrome according to the serum 
uric acid quartile and gender. Error bars indicate 95% confidence 
intervals. MS: metabolic syndrome.
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abdominal obesity is the main determinant of elevated SUA 
levels.
4)20) The lack of a significant association between the 
SUA level, BP, and fasting glucose in our study population was 
consistent with the significant associations reported by other 
investigators.
1)3)4)6)7) SUA levels were significantly correlated 
with these variables when the data of females and males were 
combined (data not shown). 
As the number of subjects with four or five components of 
the MS was small, participants with three or more compo-
nents were combined in the present study. We found a signif-
icant positive and linear relationship between SUA levels and 
the number of MS components in both genders. This result 
has also been demonstrated in other studies among Koreans
1) 
and Chinese.
6) However, gender-specific results were not re-
ported in these studies.
Regarding the relationship between SUA levels and MS sta-
tus, the present study clearly showed that a graded increase in 
the prevalence of MS with increasing SUA levels. This finding 
is in accordance with other cross-sectional studies among va-
rious ethnic groups.
1-4) However, cross-sectional studies
1-3) have 
not demonstrated whether the positive association between 
SUA and MS exists independently of the variables of MS. The 
multivariate ORs of model 2 in the present study indicate 
that the association between SUA and MS status is not inde-
pendent, but dependent on waist circumference among the 
variables of MS. When we added triglycerides instead of 
waist circumference in model 2, the OR of the highest SUA 
quartile for MS was decreased, but the statistical significance 
was maintained in the whole participants (data not shown). 
Thus, this result suggests that hyperuricemia is closely related 
to abdominal obesity among the components of MS. In a st-
udy involving a Turkish population, Onat et al.
4) showed that 
the ORs of the upper SUA tertile for MS were markedly de-
creased in females and males, but lost significance in males 
when waist circumference was added in multivariate logistic 
regression models. The presence of hyperuricemia should trig-
ger a high level of clinical suspicion and investigation for the 
potential co-existence of MS as a more potentially life-threat-
ening factor than hyperuricemia per se.
2) The present and pre-
vious cross-sectional studies
1-4) have limitations in elucidating 
of the significance of hyperuricemia in relation to MS. Two re-
cent prospective studies
21)22) are noteworthy. Hyperuricemia 
was shown to be an independent predictor of incident MS in 
MS-free Korean young male workers
21) and US middle-aged 
females and males.
22)
If an elevated SUA level is a risk factor for cardiovascular 
disease, a positive relationship between SUA levels and sur-
rogate markers of atherosclerosis is expected. Among the sur-
rogate markers of atherosclerosis, coronary artery calcifica-
tions,
13)23) carotid plaque,
3) carotid intima-media thickness
14)24)25) 
have been shown to be associated with SUA levels. However, 
the associations have not always been significant after adjust-
ment for other risk factors or according to MS status. Thus, 
it is still inconclusive whether SUA is an independent risk fac-
tor of atherosclerosis. 
In the present study we determined the relationship be-
tween the SUA level and PWV as an index of arterial stiffness, 
which is also a surrogate marker of atherosclerosis.
15)16) In con-
trary to the positive association between the SUA level and 
baPWV in Japanese individuals by Ishizaka et al.
26) and Saijo 
et al.
27) we found no association between the SUA level and 
baPWV or hfPWV. There are possible reasons why our results 
differed from that of these two studies.
26)27) First, differences 
in the baseline characteristics of a study population may ex-
plain the disparate result. Of note, are potential effects of 
morbidity and medications on PWV. For example, PWV was 
increased in patients with diabetes
28) and decreased by anti-
hypertensive drugs in hypertensive patients.
18) We excluded 
subjects with diabetes and those taking medications, such as 
antihypertensive or lipid-lowering drugs, whereas these sub-
jects were included in the study by Ishizaka et al.
26) Moreover, 
it was not reported whether the study participants were tak-
ing medications potentially affecting PWV in the study of Sai-
jo et al.,
27) except for the current use of hormone therapy for 
menopause. Age and systolic BP are the primary determinants 
p=NS p=NS
Fig. 3. Prevalence of high heart-femoral pulse wave velocity (hfPWV) 
according to the serum uric acid quartile and gender. Error bars in-
dicate 95% confidence intervals.
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of PWV.
17) However, it is unknown whether the relative im-
pact of the SUA level on PWV is changed by confounders, such 
as diabetes and antihypertensive medications, which result 
in a positive association between the SUA level and PWV. Sec-
ond, SUA levels may not affect arterial stiffness in a popula-
tion at low risk for cardiovascular disease. In the present study, 
the Framingham 10-year CHD risk reflects a low-risk cardio 
vascular profile for our study population. In fact, 84% of our 
study participants had a Framingham CHD risk <10% (data 
not shown). 
Tomiyama et al.
29) showed no independent relationship be-
tween the SUA level and baPWV in a healthy Japanese popu-
lation. Cuspidi et al.
30) showed that the SUA level was not as-
sociated with organ damage, including left ventricular hyper-
trophy, carotid alteration, or microalbuminuria, in a population 
of recently diagnosed uncomplicated hypertensives with a low 
prevalence of hyperuricemia. Although arterial stiffness was 
not measured in this study, the result could suggest that the 
SUA level is not associated with atherosclerosis in a popula-
tion at low-risk for cardiovascular disease. Third, the associ-
ation between the SUA level and PWV may depend on gender, 
MS, or MS components. 
In the study of Ishizaka et al.,
26) Pearson’s correlation coef-
ficient between the SUA level and baPWV was significant in 
females, but not in males. The SUA levels were associated 
with carotid plaque in males without MS
3) and with carotid 
intima-media thickness in males without MS
14) and in hyper-
tensive patients.
24) Although MS was associated with increased 
hfPWV or baPWV after adjustment for age and gender in the 
present study (data not shown), we found no significant cor-
relations between SUA levels and hfPWV or baPWV when we 
divided our study participants according to MS status or each 
component of MS in females and males (data not shown). 
Thus, the third reason is not likely to explain our negative re-
sults. However, we cannot completely exclude the possibility 
that our negative results were due to an insufficient number 
of participants when we were grouping our study participants. 
Thus, community-based, large population studies may be nec-
essary to determine whether SUA levels are associated with 
PWV independently of other confounding risk factors.
The strength of the present study was the relative homo-
geneity of the study subjects enhancing the internal validity 
of our findings by reducing confounding factors potentially 
affecting SUA and PWV. The limitations of the current study 
include a single center study, the number of study subjects, 
the lack of control of alcohol intake, and the cross-sectional 
nature of the study, thereby reducing the statistical power and 
precluding temporality and causal inference.
In conclusion, based on our findings, an elevated SUA level 
is associated with abdominal obesity among the MS compo-
nents and is not associated with increased PWV in Korean 
at low-risk for cardiovascular disease.
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